Fig. 2: Acquired mutations following treatment with osimertinib and comparator EGFR-TKIs. | Nature Communications

Fig. 2: Acquired mutations following treatment with osimertinib and comparator EGFR-TKIs.

From: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Fig. 2

Tile plots indicating (A) acquired mutations in patients treated with osimertinib (n = 109) and (B) acquired mutations in patients treated with comparator EGFRI-TKIs (n = 145) from the FLAURA trial. Source data are provided in the Supplementary Data 1 file. *One patient had co-occurring C797S and C797N. EGFR epidermal growth factor receptor.

Back to article page